Structural disease modification in axial spondyloarthritis
- PMID: 38042689
- DOI: 10.1016/j.berh.2023.101898
Structural disease modification in axial spondyloarthritis
Abstract
"Disease modification" in axial spondyloarthritis (axSpA) seeks to not only alleviate clinical symptoms but also alter the disease's natural course by impeding new bone formation. Recent years have witnessed the effectiveness of treatments, including biologics and nonsteroidal anti-inflammatory drugs, in managing axSpA symptoms. Emerging evidence points toward their potential impact on slowing structural disease progression. This comprehensive review centers on the pivotal role of inhibiting new bone formation in axSpA disease modification. It delves into the significance of imaging techniques for assessing disease progression and explores the disease-modifying properties of available axSpA treatments, encompassing NSAIDs, TNF inhibitors, IL-17 inhibitors, and JAK inhibitors. This article offers valuable insights into the evolving landscape of disease modification strategies in axial spondyloarthritis, highlighting the multifaceted approaches used to attain these objectives.
Keywords: Ankylosing spondylitis; Antirheumatic agents; Axial spondylarthritis; Diagnostic imaging; Disease progression; Imaging; Non-Steroidal anti-inflammatory agents; Outcomes assessment; Radiographic progression; Risk factors; Smoking; Spondylarthritis; Structural progression; Tumor necrosis factor-alpha.
Copyright © 2023 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of competing interest None.
Similar articles
-
Treatment overview of axial spondyloarthritis in 2023.Best Pract Res Clin Rheumatol. 2023 Sep;37(3):101858. doi: 10.1016/j.berh.2023.101858. Epub 2023 Sep 5. Best Pract Res Clin Rheumatol. 2023. PMID: 37673758 Review.
-
Have Therapeutics Enhanced Our Knowledge of Axial Spondyloarthritis?Curr Rheumatol Rep. 2023 Mar;25(3):56-67. doi: 10.1007/s11926-023-01097-7. Curr Rheumatol Rep. 2023. PMID: 36652160 Free PMC article. Review.
-
Treatment of axial spondyloarthritis: an update.Nat Rev Rheumatol. 2022 Apr;18(4):205-216. doi: 10.1038/s41584-022-00761-z. Epub 2022 Mar 10. Nat Rev Rheumatol. 2022. PMID: 35273385 Review.
-
Disease modification in axial spondyloarthritis.Best Pract Res Clin Rheumatol. 2018 Jun;32(3):427-439. doi: 10.1016/j.berh.2019.02.007. Epub 2019 Mar 2. Best Pract Res Clin Rheumatol. 2018. PMID: 31171313 Review.
-
Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis).Cochrane Database Syst Rev. 2015 Jul 17;2015(7):CD010952. doi: 10.1002/14651858.CD010952.pub2. Cochrane Database Syst Rev. 2015. PMID: 26186173 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
